Open Access

Therapeutic effect of ulinastatin on pulmonary fibrosis via downregulation of TGF‑β1, TNF‑α and NF‑κB

  • Authors:
    • Dejun Li
    • Hongsheng Ji
    • Bao Zhao
    • Chunyang Xu
    • Wenjun Xia
    • Lihui Han
    • Dongqing Yu
    • Yuanrong Ju
    • Changjun Jin
  • View Affiliations

  • Published online on: November 14, 2017     https://doi.org/10.3892/mmr.2017.8056
  • Pages:1717-1723
  • Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

Pulmonary fibrosis is a chronic, progressive, lethal lung disease characterized by alveolar cell necrosis and dysplasia of interstitial fibrotic tissue, resulting in loss of lung function and eventual respiratory failure. Previously, glucocorticoid drugs were used to treat this lung disorder. However, positive responses were recorded in less than half of treated patients and the cytotoxicity caused by high dosage treatment is still a concern. The present study investigated whether ulinastatin, a typical urinary trypsin inhibitor that mitigates numerous inflammatory responses, could be a treatment option for lung fibrosis. The results demonstrated that ulinastatin had the ability to ameliorate interstitial fibrosis and alveolar exudates and to protect against lung diseases induced by smoke, irradiation or silica particles. The mechanism of ulinastatin resulted in the downregulation of inflammatory cascades: Transforming growth factor‑β1, tumor necrosis factor‑α and nuclear factor‑κB, as demonstrated by western blotting and ELISA. Ulinastatin treatment with a high dose (100,000 U/kg body weight/day) resulted in an attenuated inflammatory response, and inhibited fibrosis formation in lungs, suggesting that ulinastatin may become a part of a clinical therapeutic strategy.

Related Articles

Journal Cover

January 2018
Volume 17 Issue 1

Print ISSN: 1791-2997
Online ISSN:1791-3004

2016 Impact Factor: 1.692
Ranked #19/128 Medicine Research and Experimental
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Li, D., Ji, H., Zhao, B., Xu, C., Xia, W., Han, L. ... Jin, C. (2018). Therapeutic effect of ulinastatin on pulmonary fibrosis via downregulation of TGF‑β1, TNF‑α and NF‑κB. Molecular Medicine Reports, 17, 1717-1723. https://doi.org/10.3892/mmr.2017.8056
MLA
Li, D., Ji, H., Zhao, B., Xu, C., Xia, W., Han, L., Yu, D., Ju, Y., Jin, C."Therapeutic effect of ulinastatin on pulmonary fibrosis via downregulation of TGF‑β1, TNF‑α and NF‑κB". Molecular Medicine Reports 17.1 (2018): 1717-1723.
Chicago
Li, D., Ji, H., Zhao, B., Xu, C., Xia, W., Han, L., Yu, D., Ju, Y., Jin, C."Therapeutic effect of ulinastatin on pulmonary fibrosis via downregulation of TGF‑β1, TNF‑α and NF‑κB". Molecular Medicine Reports 17, no. 1 (2018): 1717-1723. https://doi.org/10.3892/mmr.2017.8056